Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

A. Sosman, Jeffrey; B. Kim, Kevin; M. Schuchter, Lynn; González, René; C. Pavlick, Anna; S. Weber, Jeffrey; A. McArthur, Grant; E. Hutson, Thomas; J. Moschos, Stergios; T. Flaherty, Keith; Hersey, Peter; Kefford, Richard; P. Lawrence, Donald; Puzanov, Igor; D. Lewis, Karl; K. Amaravadi, Ravi; Chmielowski, Bartosz; Jeffrey Lawrence, H.; Shyr, Yu; Ye, Fei; Li, Jiang; B. Nolop, K.; J. Lee, Richard; K. Joe, Andrew; Ribas, Antoni

doi:10.1056/nejmoa1112302

Public

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

Published in New England Journal of Medicine • Feb 22, 2012

Authors:

Jeffrey A. Sosman

Kevin B. Kim

Lynn M. Schuchter

Abstract

BACKGROUND: Approximately 50% of melanomas harbor activating (V600) mutations in the serine-threonine protein kinase B-RAF (BRAF). The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF V600-mutant metastatic melanoma in a phase 1 trial and improved...

Subject

Vemurafenib

Medicine

Melanoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!